Brokerages Set Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) PT at $3.23

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has been assigned an average recommendation of “Hold” from the seven ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $3.2250.

Several brokerages have issued reports on LXRX. Citigroup lifted their price objective on Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the company a “buy” rating in a research report on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. Finally, HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Tuesday, September 2nd.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LXRX. Hudson Bay Capital Management LP bought a new position in Lexicon Pharmaceuticals in the 2nd quarter valued at $26,000. R Squared Ltd acquired a new position in shares of Lexicon Pharmaceuticals during the second quarter valued at $28,000. CWM LLC boosted its holdings in Lexicon Pharmaceuticals by 9,228.4% in the first quarter. CWM LLC now owns 105,504 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 104,373 shares during the last quarter. Catalyst Funds Management Pty Ltd acquired a new stake in Lexicon Pharmaceuticals in the second quarter worth about $51,000. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in Lexicon Pharmaceuticals by 77.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 65,330 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 28,594 shares during the last quarter. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Price Performance

NASDAQ:LXRX opened at $1.47 on Wednesday. The company has a quick ratio of 4.16, a current ratio of 4.16 and a debt-to-equity ratio of 0.43. The firm has a market cap of $534.20 million, a PE ratio of -4.45 and a beta of 1.15. Lexicon Pharmaceuticals has a 12 month low of $0.28 and a 12 month high of $1.66. The company’s 50-day moving average price is $1.37 and its two-hundred day moving average price is $1.08.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.03. The company had revenue of $14.18 million during the quarter, compared to analyst estimates of $5.81 million. Lexicon Pharmaceuticals had a negative net margin of 206.43% and a negative return on equity of 83.63%. On average, equities analysts anticipate that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.